2019-04-15
Aktien « Investor Relations - Empire Sweden AB; Tjäna pengar på att Hansa Biopharma - Genovis AB ingår förliknings- och; Kavanaugh
If you continue without making any changes you allow this. Read more about cookies here CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 8: 00am CET on April 8 2021. CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: [email protected] This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma LUND, Sweden, April 9, 2021 /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021.. In LUND, Sweden, April 9, 2021 /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021. Head of Investor Relations Hansa Biopharma AB (publ) 2019 – nu mindre än ett år.
Contact information Klaus Sindahl Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 Hansa Biopharma continues to grow and we are recruiting several interesting positions: - Senior Regulatory Affairs Manager - Investor Relations Assistant - Director Clinical Operations - QA Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM LUND, Sweden , Oct. 22, 2020 /PRNewswire/ -- Hansa Biopharma , the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for 2021-03-29 Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs' Biotech Symposium in London, Morgan Stanley's Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in … 2021-03-29 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Hansa Biopharma is based in Lund, Sweden. For further information, please contact:: Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: emanuel.bjorne@hansabiopharma.com. Swedish Investor and Media Relations: Cord Communications Mikael Widell +46-70-311-99-60 Vice President Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70-717-5477 E-mail: [email protected] 2021-03-29 Hansa Biopharma is based in Lund, Sweden. For further information, please contact: Company: Emanuel Björne, VP Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70 Milstolpebetalningarna för Hansa Biopharma kan uppgå till 397,5 miljoner dollar och därtill kommer stegrande royalties på höga ensiffriga procent upp till tvåsiffriga nivåer. I dagsläget värderar endast SEB denna option till 50 kronor per aktie då de endast tillskriver sannolikheten att det inträffar till 28 procent. Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com.
Hansa Biopharma. Scheelevägen 22 Lund, Sverige +46 46 16 56 70.
LUND, Sweden, April 9, 2021 /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021.
Huvudprojektet är en enzym som inaktiverar antikroppar och som har behandlingspotential inom organtransplantation och vid ovanliga autoimmuna sjukdomar. Hansa Biopharma Box 785 220 07 Lund Tel: +46 46 16 56 70 Fax: +46 46 12 77 75 (Besöksadress) Scheelevägen 22 223 63 Lund www.hansabiopharma.com Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR.
2 days ago
Anmäl profilen Info International profile 2021-04-09 Head of Investor Relations. klaus.sindahl@hansabiopharma.com. Hansa Biopharma.
Senior Vice President, ©2021 Hansa Biopharma. Head of Investor Relations, Hansa Biopharma Sverige Fler än 500 kontakter. Gå med för att skapa kontakt Hansa Biopharma. MIT Sloan School of
Head of Investor Relations.
Ifs world operations
HNSA Hansa Medical: CEO Søren Tulstrup presents at Redeye Life Science Day, November 21.
För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com
Se Soren Tulstrups yrkesprofil på LinkedIn. LinkedIn är världens största yrkesnätverk och hjälper yrkespersoner som Soren Tulstrup att upptäcka interna kontakter till rekommenderade jobbsökande, branschexperter och affärspartner. 2 dagar sedan · LUND, Sweden, April 14, 2021 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2021 at 8:00 CET on April 22, 2021.
Vid skilsmässa vem får huset
ica kallang
boende malmö blocket
det viktigaste
kolla registreringsskylt ägare
Hansa Biopharma interim report Jan-Sep 2020 Thu, Oct 22, 2020 08:00 CET. Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM. Lund October 22, 2020.
During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work ® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud. Careers Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform. Lund den 29 april 2019 – Hansa Biopharma AB CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase. Head of Investor Relations.